Skip to search formSkip to main contentSkip to account menu

0.5 ML lanreotide 240 MG/ML Prefilled Syringe [Somatuline]

Known as: Somatuline Depot 120 MG per 0.5 ML Prefilled Syringe, lanreotide acetate 120 mg in 0.5 mL SUBCUTANEOUS INJECTION [Somatuline Depot], 0.5 ML lanreotide 240 MG/ML ( as lanreotide acetate) Prefilled Syringe [Somatuline] 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (1)

0.5 ML lanreotide 240 MG/ML Prefilled Syringe
Prefilled SyringeSomatulineWaterlanreotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and…
4095Background: 5HIAA or CgA are biomarkers in some GEP NETs. We present posthoc analyses using prospectively collected urinary… 
Review
2016
Review
2016
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
PurposePeptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring… 
2016
2016
Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
434 Background: In the CLARINET study, significant improvement in progression-free survival (primary endpoint) was reported in… 
Review
2016
Review
2016
Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
BACKGROUND Somatostatin analogs (SSAs) are a mainstay therapy for the treatment of carcinoid syndrome associated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)